Citations

Mayo Clinic

Showing 10 of 108572 citations.

Clostridium cadaveris Septic Arthritis After Total Right Hip Arthroplasty in an Immunocompetent Host
McKenzie, Paula, Sotello, David , Fuhrmann, Kristen, Winn, Richard E., Brindley, G. V., Cuevas, José Luis , Sotello Aviles, David A

Infectious Diseases in Clinical Practice | November 9, 2016 | Volume: 25 | Issue: 3 | Pages: 165-167

10.1097/ipc.0000000000000465 Get It

Abstract An elderly woman underwent an uncomplicated right hip replacement (total hip arthroplasty) in 2005 and returned 5 years later with cellulitis of the right hip. Treatment with oral antibiotics was initiated. Septic arthritis of the right hip joint was diagnosed ultimately, and she had surgical removal (explant) of the right hip prosthesis in 2011. Recurrent right hip infections ensued on several occasions with multiple antibiotic courses over the next 4 years. Although she had intermittent infections with methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus, she had consistent and persistent isolation of Clostridium cadaveris from the hip beginning in 2013. After prolonged surgical interventions and several courses of antibiotics, C. cadaveris was eradicated; she has undergone implantation for a second stage implant (total hip arthroplasty) of the affected hip and remains stable to date.
His Bundle Refractoriness
Asirvatham, Samuel J. , Stevenson, William G. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | November 9, 2016 | Volume: 9 | Issue: 11 | Pages: No page available

10.1161/circep.116.004719 | PMID 27906656 Get It

Big Science
Montori, Víctor M. , Montori, Victor M

Circulation: Cardiovascular Quality and Outcomes | November 9, 2016 | Volume: 9 | Issue: 6 | Pages: 688-692

10.1161/circoutcomes.116.003358 | PMID 28263944 Get It

Postoperative Pulmonary Complications, Early Mortality, and Hospital Stay Following Noncardiothoracic Surgery
Frendl, György , Kor, Daryl J. , Subramaniam, Bala , Ruiz, Ricardo Martinez, Lee, Jae Woo , Henderson, William G., Moss, Angela , Mehdiratta, Nitin , Colwell, Megan M., Bartels, Karsten , Kolodzie, Kerstin , Giquel, Jadelis, Melo, Marcos Francisco Vidal, Fernandez-Bustamante, Ana , Šprung, Juraj

JAMA Surgery | November 9, 2016 | Volume: 152 | Issue: 2 | Pages: 157

10.1001/jamasurg.2016.4065 | PMID 27829093 Get It

Ethnic differences in all-cause and cardiovascular mortality by physical activity levels among older adults in the US
Vásquez, Elizabeth , Sahakyan, Karine , Germain, Cassandra , Shaw, Benjamín A. , Batsis, John A. , Somers, Virend K.

Ethnicity & Health | November 9, 2016 | Volume: 23 | Issue: 1 | Pages: 72-80

10.1080/13557858.2016.1253830 | PMID 27825247 Get It

Utility of endoscopic therapy in the management of Boerhaave syndrome
Dickinson, Karen J., Buttar, Navtej , Song, Louis Wong Kee, Gostout, C. J., Cassivi, S.D., Nichols, Francis, Shen, K. Robert , Wigle, Dennis A. , Allen, Mark S. , Nichols, Francis C., Blackmon, Shanda

Endoscopy International Open | November 8, 2016 | Volume: 04 | Issue: 11 | Pages: E1146-E1150

10.1055/s-0042-117215 | PMID 27853740 Get It

Care Across the Cancer Continuum
Wordingham, Sara E., Mayer, Gregory K.

Journal of Women's Health | November 8, 2016 | Volume: 26 | Issue: 7 | Pages: 815-816

10.1089/jwh.2016.6096 | PMID 27824516 Get It

Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP‐17) due to microtubule‐associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy
Tacik, Paweł , DeTure, Michael , Murray, Melissa E. , Rademakers, Rosa , Ross, Owen A. , Wszolek, Z.K. , Parisi, J. E., Petersen, Ronald C. , Sánchez-Contreras, Mónica , Knopman, David S. , Dickson, Dennis W. , Ross, Owen A , Murray, Melissa E

Neuropathology and Applied Neurobiology | November 8, 2016 | Volume: 43 | Issue: 3 | Pages: 200-214

10.1111/nan.12367 | PMID 27859539 Get It

AimThe p.P301L mutation in microtubule‐associated protein tau (MAPT) is a common cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP‐17). We compare clinicopathologic features of five unrelated and three related (brother, sister and cousin) patients with FTDP‐17 due to p.P301L mutation.MethodsGenealogical, clinical, neuropathologic and genetic data were reviewed from eight individuals.ResultsThe series consisted of five men and three women with an average age of death of 58 years (52–65 years) and average disease duration of 9 years (3–14 years). The first symptoms were those of behavioural variant frontotemporal dementia in seven patients and semantic variant of primary progressive aphasia in one. Three patients were homozygous for the MAPT H1 haplotype; five had H1/H2 genotype. The apolipoprotein E genotype was ϵ3/ϵ3 in seven and ϵ3/ϵ4 in one. The average brain weight was 1015 g (876–1188 g). All had frontotemporal lobar or more diffuse cortical atrophy. Except for one patient, the hippocampus and parahippocampal gyrus had minimal atrophy, whereas there was atrophy of middle and inferior temporal gyri. Dentate fascia neuronal dispersion was identified in three patients, two of whom had epilepsy. In one patient there was extensive white matter tau involvement with Gallyas‐positive globular glial inclusions typical of globular glial tauopathy (GGT).ConclusionsThis clinicopathologic study shows inter‐ and intra‐familial clinicopathologic heterogeneity of FTDP‐17 due to MAPT p.P301L mutation, including GGT in one patient.
Prediagnostic alcohol consumption and colorectal cancer survival: The Colon Cancer Family Registry
Phipps, Amanda I. , Robinson, Jamaica R.M. , Win, Aung Ko , Figueiredo, Jane C. , Lindor, Noralane M. , Campbell, Peter T. , Newcomb, Polly A. , Win, Aung K

Cancer | November 8, 2016 | Volume: 123 | Issue: 6 | Pages: 1035-1043

10.1002/cncr.30446 | PMID 27861761 Get It

BACKGROUNDAlthough previous studies have noted an increased risk of colorectal cancer (CRC) among moderate to heavy alcohol consumers in comparison with nondrinkers, the relation between alcohol consumption and CRC survival remains unclear.METHODSCases of incident invasive CRC diagnosed between 1997 and 2007 were identified via population‐based cancer registries at 4 study sites in the Colon Cancer Family Registry. Study participants completed a risk‐factor questionnaire on prediagnostic behaviors, including wine, beer, and liquor consumption, at the baseline. Prospective follow‐up for survival was conducted for 4966 CRC cases. Cox regression was used to compare nondrinkers with individuals who consumed, on average, 1 or more servings of alcohol per day in the years preceding their CRC diagnosis with respect to overall and disease‐specific survival. Separate analyses by beverage type, stratified by patient and tumor attributes, were also performed. All models were adjusted for the age at diagnosis, sex, study site, year of diagnosis, smoking history, body mass index, and education.RESULTSPrediagnostic beer and liquor consumption was not associated with CRC survival; however, higher levels of wine consumption were modestly associated with a better prognosis overall (CRC‐specific hazard ratio [HR], 0.70, 95% confidence interval [CI], 0.48‐1.03; overall HR, 0.70; 95% CI, 0.53‐0.94). Similar patterns were noted in stratified analyses.CONCLUSIONSThese findings suggest that prediagnostic wine consumption is modestly associated with more favorable survival after CRC. Cancer 2017;123:1035–43. © 2016 American Cancer Society.
Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database
Bergquist, John R. , Spindler, Blake A., Shubert, Christopher R. , Hayman, Amanda V., Habermann, Elizabeth B. , Pembérton, John H., Mathis, Kellie L. , Thiels, Cornelius A. , Kelley, Scott R. , Larson, David W. , Habermann, Elizabeth , Bergquist, John R

Diseases of the Colon & Rectum | November 8, 2016 | Volume: 59 | Issue: 12 | Pages: 1142-1149

10.1097/dcr.0000000000000699 | PMID 27824699 Get It

BACKGROUND: Clinical trials demonstrate that postresection chemotherapy conveys survival benefit to patients with stage III colon cancer. It is unclear whether this benefit can be extrapolated to the elderly, who are underenrolled in clinical trials. OBJECTIVE: The purpose of this study was to determine outcomes of selected octogenarians with stage III colon cancer with/without postresection adjuvant therapy. DESIGN: This was a retrospective cohort study (2006–2011) using unadjusted Kaplan–Meier and adjusted Cox proportional hazards analyses of overall survival. SETTING: The study was conducted with the National Cancer Database. PATIENTS: We included patients 80 to 89 years of age who were undergoing curative-intent surgery for stage III colon cancer and excluded patients who received neoadjuvant therapy, died within 6 weeks of surgery, or had high comorbidity. MAIN OUTCOME MEASURES: Overall survival was the main measure. RESULTS: A total of 8141 octogenarians were included; 3483 (42.8%) received postresection chemotherapy, and 4658 (57.2%) underwent surgery alone. Patients receiving chemotherapy were younger (82.0 vs 84.0 years; p < 0.001), healthier (73.1% vs 70.4% with no comorbidities; p = 0.009), and more likely to have N2 disease (40.4% vs 32.8%; p < 0.001). Overall survival was improved in patients receiving adjuvant chemotherapy (median = 61.7 vs 35.0 months; p < 0.001). Subgroup analysis of patients offered chemotherapy but refusing (n = 1315) demonstrated overall survival worse than those receiving adjuvant chemotherapy (median = 42.7 vs 61.7 months; p < 0.001). Multivariable analysis adjusting for potential confounders showed therapy with surgery alone to be independently associated with increased mortality hazard (HR = 1.83; p < 0.001), and the mortality hazard remained elevated in patients who voluntarily refused adjuvant therapy (HR = 1.45; p < 0.001). LIMITATIONS: The study was limited by its retrospective, nonrandomized design. CONCLUSIONS: In selected octogenarians with stage III colon cancer, postresection adjuvant chemotherapy was associated with superior overall survival. However, less than half of the octogenarians with stage III colon cancer in the National Cancer Database received it. The remaining majority, who were all fit and survived ≥6 weeks postsurgery, could have derived benefit from adjuvant chemotherapy. This represents a substantial opportunity for quality improvement in treating octogenarians with stage III colon cancer.